Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis

Area of Science:

• Orthopedics
• Biomaterials Science
• Pharmacology

Background:

• Glucocorticoids increase bone fragility and fracture risk.
• Standard bone densitometry lacks sensitivity for early glucocorticoid-induced bone changes.
• Densitometry partially assesses osteoporosis treatment efficacy.

Purpose of the Study:

• To evaluate reference point indentation for detecting early bone tissue property changes after glucocorticoid initiation.
• To compare reference point indentation's sensitivity against bone densitometry in patients on glucocorticoids and osteoporosis therapies.

Main Methods:

• Reference point indentation measured bone material strength index (BMSi) on tibial cortical bone.
• Bone mineral density (BMD) was assessed using dual-energy X-ray absorptiometry (DXA).
• Patients received calcium + vitamin D, risedronate, denosumab, or teriparatide.

Main Results:

• Calcium + vitamin D group showed significant BMSi deterioration.
• Risedronate group had no significant BMSi change.
• Denosumab and teriparatide groups demonstrated significant BMSi improvement within 7-20 weeks.
• No significant DXA-measured BMD changes were observed during the study.

Conclusions:

• Reference point indentation is sensitive to early cortical bone changes induced by glucocorticoids.
• This technique reflects treatment responses to osteoporosis therapies more effectively than densitometry.
• Reference point indentation shows potential for monitoring bone health in patients on glucocorticoids.